Procter & Gamble Health Ltd
₹5015
-47.50 (0.94%)
Wed, 28 Oct 2026, 11:31 pm
Health Technology
Pharmaceuticals: Major
24.5KProcter & Gamble Health PE Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 13.32 | 11.14 | 5.64 | 10.96 | 8.09 | 14.80 | 18.81 | 15.50 | 13.77 | 16.65 | 30.57 | 24.12 | 20.91 | 22.78 | 6.10 | 39.86 | 52.52 | 36.10 | 37.97 | 36.41 |
| Price to book ratio | 3.81 | 2.94 | 1.91 | 1.78 | 1.13 | 2.05 | 3.43 | 2.41 | 2.23 | 1.78 | 2.38 | 2.19 | 2.49 | 2.92 | 3.32 | 7.45 | 13.20 | 11.28 | 11.61 | 15.90 |
| Price to sales ratio | 2.52 | 2.23 | 2.28 | 2.39 | 1.31 | 2.05 | 2.34 | 1.77 | 1.58 | 1.17 | 1.52 | 1.38 | 1.67 | 3.06 | 6.04 | 7.47 | 9.21 | 6.25 | 7.09 | 6.85 |
| Price to cash flow ratio | 12.05 | 11.37 | 9.28 | 12.49 | 15.29 | 14.86 | 13.34 | 0 | 15.51 | 46.51 | 54.70 | 12.97 | 13.48 | 29.10 | 0 | 22.81 | 35.13 | 38.74 | 34.83 | 48.54 |
| Enterprise value | 900Cr | 793Cr | 646Cr | 637Cr | 326Cr | 643Cr | 1047Cr | 875Cr | 862Cr | 720Cr | 1131Cr | 1063Cr | 1349Cr | 1791Cr | 3876Cr | 6112Cr | 8824Cr | 6629Cr | 8285Cr | 8355Cr |
| Enterprise value to EBITDA ratio | 8.61 | 7.39 | 8.26 | 9.64 | 6.72 | 10.68 | 14.18 | 21.51 | 8.52 | 9.79 | 19.89 | 12.45 | 10.72 | 18.67 | 25.98 | 28.28 | 34.89 | 24.47 | 25.18 | 19.32 |
| Debt to equity ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0 | 0.02 | 0.01 |
| Return on equity % | 31.95 | 28.84 | 38.59 | 16.87 | 14.41 | 14.26 | 15.53 | 16.84 | 17.54 | 11.10 | 8.02 | 9.35 | 12.61 | 8.74 | 8.95 | 0 | 21.96 | 29.17 | 33.57 | 48.55 |
Procter & Gamble Health Ltd Price to Earnings Ratio
The Procter & Gamble Health Ltd Price to Earnings Ratio is a key financial metric used by investors to evaluate Procter & Gamble Health Ltd's valuation, profitability, and overall financial performance. Tracking the Procter & Gamble Health Ltd Price to Earnings Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Procter & Gamble Health Ltd (NSE: PGHL, BSE: 500126) is currently trading at ₹5015, with a market capitalization of ₹8354.05Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Procter & Gamble Health Ltd Price to Earnings Ratio is essential for fundamental analysis.
Procter & Gamble Health Ltd Price to Earnings Ratio Current Value
The current Procter & Gamble Health Ltd Price to Earnings Ratio stands at 36.41.
The Procter & Gamble Health Ltd Price to Earnings Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Procter & Gamble Health Ltd Price to Earnings Ratio Historical Trend
The Procter & Gamble Health Ltd Price to Earnings Ratio has shown the following historical trend:
- 2025: 36.41
- 2024: 37.97
- 2023: 36.10
- 2022: 52.52
- 2021: 39.86
The decline in Procter & Gamble Health Ltd Price to Earnings Ratio indicates improving financial efficiency or better earnings growth.
What Procter & Gamble Health Ltd Price to Earnings Ratio Indicates for Investors
The Procter & Gamble Health Ltd Price to Earnings Ratio plays a crucial role in understanding the company's financial health and valuation.
A higher P/E ratio indicates investors expect strong future earnings growth, while a lower ratio may signal undervaluation.
Procter & Gamble Health Ltd Price to Earnings Ratio Analysis Summary
The Procter & Gamble Health Ltd Price to Earnings Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Procter & Gamble Health Ltd Price to Earnings Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Procter & Gamble Health Ltd Price to Earnings Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
